Table 2.

Clinical, immunohistochemical, and molecular variables between tumors with and without TP53 mutations

Tumors with TP53 mutationTumors with wild-type TP53P
Patients, n (%)12 (33)24 (66)
Age, y (mean ± SD)46 ± 16.544.1 ± 16.3NS*
Glucocorticoid secretion, n (%)10 (83)15 (63)NS
Tumor weight, g [median (min-max)]640 (281-2,200)185 (43-2,700)0.02
Weiss score ≥4, n (%)10 (83)19 (83)NS
MacFarlane score 2 vs 3-4, n (%)9 (75)8 (33)0.02
VNTR1 LOH, n (%)5 (42)11 (46)NS
11p15 LOH, n (%)9/11 informative cases (81)21/23 informative cases (91)NS
IGF-II overexpression, n (%)9/12 (75)18/22 (82)NS
p53 overexpression by immunohistochemistry, n (%)6/6 (100)0/10 (0)<0.01
  • Abbreviation: IGF-II, insulin-like growth factor-II.

  • * Nonsignificant (P > 0.05).